Mario Cozzolino

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Alberto Ortíz, Mario Cozzolino, Danilo Fliser et al. · Nephrology Dialysis Transplantation · 2020 · 363 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D

Mario Cozzolino, Marcos Vidal, A Vittoria et al. · AIDS · 2003 · 221 citations

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 205 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9